Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
406 hedge funds and large institutions have $17.3B invested in Alexion Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 406 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
53% more call options, than puts
Call options by funds: $149M | Put options by funds: $97.1M
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PFO
401
Pathstone Family Office
Englewood,
New Jersey
| $2K | +$2.22K | +23 | New |
|
|
RFA
402
Reilly Financial Advisors
La Mesa,
California
| $2K | +$2.41K | +25 | New |
|
|
EFSCE
403
Enterprise Financial Services Corp (EFSC)
Clayton,
Missouri
| $2K | +$2.6K | +27 | New |
|
|
CAM
404
ClariVest Asset Management
San Diego,
California
| $1K | +$964 | +10 | New |
|
405
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
| $627 | +$655K | +6,800 | New |
|
|
PG
406
PEAK6 Group
Chicago,
Illinois
| $526 | +$549K | +5,700 | New |
|
ALXN Hedge Fund Activity: Q2 2013 in Review
406 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2013, worth a combined $17.3B.
Buyers outnumbered sellers: 406 funds opened new ALXN positions and 0 closed out — a net gain of 406 holders — while 0 added to existing stakes and 0 trimmed.
- 406 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $17.3B of Alexion Pharmaceuticals stock for Q2 2013.
- 406 funds opened new Alexion Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +406 holders.
Based on aggregated 13F filings for Q2 2013.